1. LBA-001Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial. (2nd July 2019) Authors: Golan, T; Hammel, P; Reni, M; Van Cutsem, E; Macarulla, T; Hall, M; Park, J; Hochhauser, D; Arnold, D; Oh, D; Reinacher-Schick, A; Tortora, G; Algül, H; O'Reilly, E; McGuinness, D; Cui, K; Schlienger, K; Locker, G; Kindler, H Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PD-001Analysis of patient screening in the phase III, international, randomized, open-label APACT trial. (2nd July 2019) Authors: Reni, M; Winter, J; Tortora, G; Pelzer, U; Riess, H; Chang, H; O'Reilly, E; Oh, D; Diaz, I Alés; Milella, M; Bendell, J; Garlipp, B; Tempero, M; Macarulla, T; Van Cutsem, E; Berlin, J; Goldstein, D; Lu, B; Jeanes, J; Philip, P Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-225Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. (2nd July 2019) Authors: Javle, M; Borbath, I; Clarke, S; Hitre, E; Louvet, C; Macarulla, T; Oh, D; Spratlin, J; Valle, J; Weiss, K; Berman, C; Howland, M; Ye, Y; Cho, T; Moran, S; Abou-Alfa, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. O-001An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. (2nd July 2019) Authors: Reni, M; Riess, H; O'Reilly, E; Santoro, A; Park, J; Bekaii-Saab, T; Tempero, M; Shan, Y; Macarulla, T; Cutsem, E Van; Noel, M; Berlin, J; Biankin, A; Dhani, N; Frassineti, G; Goldstein, D; Romano, A; Bruchec, Y Le; Philip, P Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SO-005A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer. (2nd July 2019) Authors: Wainberg, Z; Boland, P; Lieu, C; Dayyani, F; Macarulla, T; Zhang, B; Belanger, B; Moore, Y; Wang, T; Maxwell, F; Dean, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. O-002Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. (2nd July 2019) Authors: Tempero, M; Oh, D; Macarulla, T; Reni, M; Cutsem, E Van; Hendifar, A; Waldschmidt, D; Starling, N; Bachet, J; Chang, H; Maurel, J; Lonardi, S; Coussens, L; Fong, L; Tsao, L; Cole, G; James, D; Tabernero, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. (23rd October 2018) Authors: Javle, M; Kelley, R K; Roychowdhury, S; Weiss, K H; Abou-Alfa, G K; Macarulla, T; Sadeghi, S; Waldschmidt, D; Zhu, A X; Goyal, L; Borad, M; Yong, W P; Borbath, I; El-Khoueiry, A; Philip, P; Moran, S; Ye, Y; Ising, M; Lewis, N; Bekaii-Saab, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P-160Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first‐line chemotherapy in routine practice. (20th June 2018) Authors: Velasco, A García; Macarulla, T; Sánchez, C Bugés; Martín, M; García, C; Pericay, C; Merino, S; Visa, L; Martín, T; Pedraza, M; Carnero, B; Guardeño, R; Pellín, L; Vilanova, D; Laquente, B Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P-182Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress. (20th June 2018) Authors: Qin, S; Finn, R; Kudo, M; Meyer, T; Vogel, A; Ducreux, M; Macarulla, T; Tomasello, G; Boisserie, F; Hou, J; Li, C; Song, J; Zhu, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P-160Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first‐line chemotherapy in routine practice. (20th June 2018) Authors: Velasco, A García; Macarulla, T; Sánchez, C Bugés; Martín, M; García, C; Pericay, C; Merino, S; Visa, L; Martín, T; Pedraza, M; Carnero, B; Guardeño, R; Pellín, L; Vilanova, D; Laquente, B Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗